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See Article, pages 283–290Ascites is one of the most frequent complications of cirrhosis.
Indeed, ascites develops in about 50% of cirrhotic patients and
in many of them it will become refractory ascites, which is
deﬁned as an ascites that cannot be mobilized by the standard
therapy with dietary salt restriction and with diuretic medica-
tions at doses of up to 160 mg/day of furosemide and 400 mg/
day of spironolactone [1].
The quality of life of patients with refractory ascites progres-
sively deteriorates. Their risk in developing other portal hyper-
tension-related complications is high, and their probability of
survival is strongly reduced.
Liver transplantation is the only treatment which allows for
bypassing these problems; however, only a small subgroup of
patients with refractory ascites ever has the chance to be success-
fully transplanted.
In most patients refractory ascites is treated conservatively.
The main goal of treatment is to relieve tense ascites, to prevent
further complications such as renal failure, encephalopathy,
cramps, and herniations, and to prolong survival so that the
chances for receiving liver transplantion are improved.
To date, the standard treatment for refractory ascites is
repeated large-volume paracentesis (LVP) combined with an
i.v. infusion of albumin [2]. LVP has been shown to have less
side effects than diuretic treatment [3] and is at least as effec-
tive as a LeVeen shunt, a treatment that has almost been com-
pletely abandoned due to the high rate of malfunction or
obstruction of the shunt [4]. LVP allows for rapid relief of
the abdominal tension created by ascites. However, since LVP
does not correct the mechanisms causing ascites, ascites re-
accumulates and paracentesis must be repeated after a variable
period of time. Some patients that have a very low capacity to
excrete sodium, re-accumulate ascites so rapidly that paracen-
tesis must be repeated every few days, which is very inconve-
nient for the patient. Alternatively, the insertion of a
transjugular intrahepatic portosystemic stent shunt (TIPS),
which reduces portal pressure, has been demonstrated to be
able to reduce ascites formation, avoid paracentesis, and, in
well-selected patients, improve survival [5]. Accordingly, some
consider TIPS as the ﬁrst option for the treatment of patients
with refractory ascites. However, many cirrhotic patients with
refractory ascites cannot be treated with TIPS because of con-Journal of Hepatology 20
* Corresponding author. Address: Policlinico IRCCS San Donato, University of
Milan, Via Morandi 30, 20097 San Donato (MI), Italy. Tel.:/fax: +39 02 52774462.
E-mail address: francesco.salerno@unimi.it (F. Salerno).
Open access under CC BY-NC-ND license.traindications, the most frequent of which are encephalopathy,
hyperbilirubinemia, high Child-Pugh score, cardiorespiratory
failure, pulmonary hypertension, older age, porto-mesenteric
thrombosis, intrahepatic bile ducts dilatation, and polycystic
liver disease. For this reason TIPS should be reserved for
patients who do not tolerate repeated LVP and who do not
show any of the aforementioned contraindications. This group
of patients represents more or less 40–50% of cirrhotic patients
with refractory ascites [6].
There are no other conservative treatments currently avail-
able. Therefore, the possibility of combining diuretics with new
drugs resulting in a better control of ascites, without increasing
the risk of side-effects, is a relevant issue. An improvement in
the effect of diuretic medications could be obtained with the
chronic administration of albumin [7] or with vasoconstrictor
agents which reduce splanchnic blood ﬂow. Terlipressin must
be given intravenously and is too expensive to be used chroni-
cally, while midodrine can be given orally, is cheaper, and has
been demonstrated to increase urine sodium excretion when
given after LVP [8]. However, we need powerful RCTs to conﬁrm
the utility of these strategies.
Arginine–vasopressin-receptor antagonists, or vaptans, are a
new class of drugs able to increase free water excretion. They
work as antagonists of the V2 receptors of vasopressin, which
are located in the principal cells of the renal-collecting-duct sys-
tem. As these receptors regulate the reabsorption of free water,
their inhibition increases water excretion causing a reduction in
urine osmolality and an increase in plasma osmolality [9]. There-
fore, the main indication for giving vaptans is the treatment of
euvolemic or hypervolemic hyponatremia caused by an inappro-
priate release of antidiuretic hormone [10].
Some peptide vasopressin-receptor antagonists have been
developed since the 1960s. However, the need for parenteral
administration and the unexpected property of an intrinsic ago-
nistic effect, in addition to the antagonistic effects, precluded
their widespread or chronic use in patients [11].
By contrast, the new non-peptide vasopressin-receptor antag-
onists, or vaptans, are orally active and seem to maintain their
antagonistic effect also when given chronically.
Many human disorders are associated with hyponatremia.
Vaptans have been tested in various clinical disorders with hypo-
natremia, mainly in acute and chronic cardiac failure [12–13].
Five non-peptide antagonists are now at various stages in
randomized controlled trials (RCTs) (Table 1).
Some of them have also been tested in cirrhotic patients
with the aim of correcting hyponatremia [11,14], and in some10 vol. 53 j 225–227
Table 1. No-peptide V2-receptor antagonists.
Generic name Tolvaptan Lixivaptam Satavaptan Mozavaptan Conivaptan
Administration Oral Oral Oral or iv Oral Oral or iv
Dose 15–60 mg 50–100 mg 5–25 30–60 40–80
Selective index (Va1/V2) 29 100 112 10 0–15
Half life (h) 6–8 7–10 14–17 31–78
Metabolism Hepatic Hepatic Hepatic Hepatic Hepatic
Editorialcases, to reduce oedema. The rationale for the latter indica-
tion is that by increasing free water excretion, vaptans can
cause a moderate hypovolemia and thus induce oedema
reabsorption.
In the present issue of the Journal, Wong et al. [15] report
the results of a RCT where three different doses of Satavaptan
(5, 12.5, and 25 mg/day) and a placebo were given to hypo-
or normo-natremic cirrhotic patients with ascites which periodi-
cally required LVP. All subjects also received a small dose of
spironolactone (100 mg). The main endpoints of the study were
the length of the interval between two consecutive paracentesis
and the weekly amount of ascites accumulation estimated by
summing up the litres of ascites removed with paracentesis and
by following the changes in kilograms of body weight. A second-
ary end-point was the total number of paracentesis performed
during 12 weeks of treatment. The trial was double-blind and
was based on the rationale that increasing the urine volume by
antagonizing the renal effects of arginine–vasopressin can delay
the recurrence of ascites after paracentesis. A possible enhance-
ment of the diuretic power of spironalactone was also possible,
since Satavaptan was shown to transiently increase sodium
excretion [16].
By a statistical point of view, the main end-points of the study
were not achieved, even if the total number of paracentesis per-
formed during the 12 weeks of observation was signiﬁcantly
lower in patients taking Satavaptan.
Thus, these data suggest that the administration of an antag-
onist of the V2 receptors of arginine–vasopressin to patients with
advanced cirrhosis and ascites may produce only a minor effect in
the control of ascites. Taking into account that some side-effects
frequently occurred in patients treated with Satavaptan, such as
orthostatic hypotension, encephalopathy, muscle cramps, and
hyperkalemia, the use of Satavaptan could cause more trouble
than it is worth.
However, there are a series of issues that deserve to be consid-
ered before giving a ﬁnal evaluation on the effects of Satavaptan
in cirrhotic patients with severe ascites.
First, in this study Satavaptan was combined with 100 mg/day
of spironolactone, a very small dose for patients with a long-last-
ing history of ascites (more than one year). Accordingly, we can-
not predict what could be the effect of Satavaptan given with
higher doses of spironolactone or in association with a combina-
tion of spironolactone and furosemide that is the more common
therapy in cirrhotic patients with severe (but not refractory)
ascites.
Second, the best effects were obtained with the ﬁrst two doses
of Satavaptan (5 and 12.5 mg) and there was not a dose-
dependent effect. This brings up the possibility that a dose lower
than 5 mg/day could be equally effective and produce less side-
effects.
Third, 57 (38%) out of 151 patients did not complete the
study; for many this was due to drug intolerance. A similar
number of discontinuations may have considerably affected the
results.226 Journal of Hepatology 201Lastly, the efﬁcacy and safety of Satavaptan for longer periods
of time is still unknown. Obtaining this information will be nec-
essary in order to evaluate the risk/beneﬁt ratio for the chronic
use of Satavaptan outside RCTs.
In conclusion, Satavaptan is a potent antagonist of the renal
effects of arginine–vasopressin that, in combination with diuret-
ics, could play a role in the treatment of recurrent or refractory
ascites, as well as in the correction of hyponatremia. These poten-
tialities make Satavaptan a drug of great interest for cirrhotic
patients as well as for patients with other oedemigeneous disor-
ders. However, we need to answer questions that are still unre-
solved regarding their use. In particular, whereas the ability to
correct hyponatremia is a well-proven therapeutic effect, the
ability to improve the management of severe ascites should still
be tested with further RCTs.Conﬂicts of interest
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